Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma

Melanoma and Skin Cancer

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

N Engl J Med.

Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Schadendorf D, Lesimple T, Plummer R, Ji R, Zhang P, Mookerjee B, Legos J, Kefford R, Dummer R, Kirkwood JM

doi: 10.1056/NEJMoa1708539.

Melanoma and Skin Cancer

Clinical significance of BRAF/NRAS concurrent mutations in a clinic-based metastatic melanoma cohort

Br J Dermatol.

Del Regno L, Louveau B, Battistella M, Sadoux A, Baroudjian B, Delyon J, Serror K, Allayous C, Lebbe C, Mourah S, Jouenne F

doi: 10.1111/bjd.18641.

Melanoma and Skin CancerImmunotherapy

PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma

JAMA Ophthalmol.

Gezgin G, Luk SJ, Cao J, Dogrusöz M, van der Steen DM, Hagedoorn RS, Krijgsman D, van der Velden PA, Field MG, Luyten GPM, Szuhai K, Harbour JW, Jordanova ES, Heemskerk MHM, Jager MJ

Melanoma and Skin Cancer

Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib

Eur J Cancer

Saiag P, Robert C, Grob JJ, Mortier L, Dereure O, Lebbe C, Mansard S, Grange F, Neidhardt EM, Lesimple T, Machet L, Bedane C, Maillard H, Dalac-Rat S, Nardin C, Szenik A, Denden A, Dutriaux C

doi: 10.1016/j.ejca.2021.05.031

Melanoma and Skin Cancer

Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study

Melanoma Res.

Drago JZ, Lawrence D, Livingstone E, Zimmer L, Chen T, Giobbie-Hurder A, Amann VC, Mangana J, Siano M, Zippelius A, Dummer R, Goldinger SM, Sullivan RJ

doi: 10.1097/CMR.

Melanoma and Skin CancerImmunotherapy

Immunomodulatory effects of BRAF and MEK Inhibitors: Implications for Melanoma therapy

Pharmacol Res.

Kuske M, Westphal D, Wehner R, Schmitz M, Beissert S, Praetorius C, Meier F

doi: 10.1016/j.phrs.2018.08.019.

Melanoma and Skin Cancer

Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma

Melanoma Res

Adams AM, Chick RC, Vreeland TJ, Clifton GT, Hale DF, McCarthy PM, O'Shea AE, Bohan PMK, Hickerson AT, Park H, Sloan AJ, Hyngstrom J, Berger AC, Jakub JW, Sussman JJ, Shaheen M, Wagner T, Faries MB, Peoples GE

doi: 10.1097/CMR.0000000000000758

Melanoma and Skin Cancer

Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study

Melanoma Res

Tacar SY, Selcukbiricik F, Yilmaz M, Erturk K, Murat Sarici A, Gulturk I, Ayhan M, Tural D

doi: 10.1097/CMR.0000000000000744

Melanoma and Skin CancerFurther Publications Dermatology

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

N Engl J Med

Nathan P, Hassel JC, Rutkowski P, Baurain JF, Butler MO, Schlaak M, Sullivan RJ, Ochsenreither S, Dummer R, Kirkwood JM, Joshua AM, Sacco JJ, Shoushtari AN, Orloff M, Piulats JM, Milhem M, Salama AKS, Curti B, Demidov L, Gastaud L, Mauch C, Yushak M, Carvajal RD, Hamid O, Abdullah SE, Holland C, Goodall H, Piperno-Neumann S, IMCgp100-202 Investigators.

doi: 10.1056/NEJMoa2103485

Related content

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

Clinical significance of BRAF/NRAS concurrent mutations in a clinic-based metastatic melanoma cohort

PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma

Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib

Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study

Immunomodulatory effects of BRAF and MEK Inhibitors: Implications for Melanoma therapy

Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma

Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma